Longeveron Inc. announced the effective date for its previously approved one-for-ten reverse stock split of Class A and Class B common stock. The split becomes effective at 11:59 p.m. Eastern Time on August 26, 2026, with split-adjusted trading beginning on August 27, 2026, under the ticker symbol LGVN on the Nasdaq Capital Market. This structural adjustment aims to increase the per-share trading price to regain compliance with Nasdaq’s $1.00 minimum bid price requirement and aligns with institutional investor preferences. The transaction reduces outstanding Class A shares from approximately 30.4 million to 3.0 million and Class B shares from approximately 1.4 million to 144,901. Longeveron is a clinical-stage biotechnology company developing cellular therapies for rare pediatric and chronic aging-related conditions.
